Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized trial of gemcitabine plus docetaxel vs. docetaxel plus capecitabine in metastatic breast cancer in 1st and 2nd line patients.

Next Previous
X
Search
Trial Profile

Randomized trial of gemcitabine plus docetaxel vs. docetaxel plus capecitabine in metastatic breast cancer in 1st and 2nd line patients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Capecitabine; Docetaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 26 Nov 2008 Status changed from active, no longer recruiting to completed.
    • 27 Dec 2007 The expected completion date for this trial is now Jun 2008 according to ClinicalTrials.gov.
    • 06 Sep 2006 Status change

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top